2008 Press Releases

• Tranzyme Pharma's Ghrelin Agonist TZP-101 Shows Potential as a Potent Agent for Cancer Cachexia

  October 16, 2008

• Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)

  October 1, 2008

• Tranzyme Pharma Receives Notices of Allowance from USPTO on Two Patents Protecting Companyís Lead Pharmaceutical Development Programs

  July 22, 2008

• Tranzyme Pharma Announces Successful Thorough QT/QTc Study of Ghrelin Agonist TZP-101

  June 23, 2008

• Tranzyme Pharma’s Ghrelin Agonist TZP-102 Demonstrates Safety and High Oral Bioavailability in the Successful Completion of a Phase I Trial

  June 17, 2008

• Tranzyme Pharma to Present “Ghrelin Agonist (TZP-101) Effects on Patients with Severe Symptomatic Diabetic Gastroparesis” at ADA 2008

  June 5, 2008

• Tranzyme Pharma Receives IND Clearance for Its Oral Ghrelin Agonist, TZP-102, for the Treatment of Gastroparesis

  January 29, 2008

Archives

• 2009 Press Releases
• 2008 Press Releases
• 2007 Press Releases
• 2006 Press Releases
• 2005 Press Releases
• 2004 Press Releases
• 2003 Press Releases